The use of ectoine nasal spray in combination therapy of allergic rhinitis, the possibilities of barrier monotherapy

Abstract

В представленном исследовании произведено изучение сравнительной эффективности применения препарата Аква Марис® Сенс в качестве монопрепарата при лечении аллергического ринита, а также его комбинации с интраназальными глюкокортикостероидами. Под наблюдением находилось 90 пациентов с диагнозом аллергический ринит, интермиттирующая форма. Применение данного спрея направлено на создание особой гидрофильной пленки на поверхности слизистой полости носа для предупреждения попадания на слизистую оболочку аллергенов и снижения трансбарьерной сенсибилизации. Использование назального спрея Аква Марис® Сенс способствует снижению симптомов заболевания с улучшением качества жизни пациентов и в особенности оправдано у больных, имеющих противопоказания для стандартной фармакотерапии аллергического ринита. Ключевые слова: аллергический ринит, эктоин. Библиография: 5 источников. The work presents comparative study of the efficacy of the preparation Aqua Maris® Sens as a monodrug in the treatment of allergic rhinitis, as well as its combination with intranasal glucocorticosteroids. We observed 90 patients with the diagnosis of allergic rhinitis in intermittent form. The use of this spray is aimed at formation of a special hydrophilic film on the surface of the nasal mucosa to prevent contact with allergens and reduce mucous trans-barrier sensibilization. Using the nasal spray Aqua Maris® Sens provides reduction of the disease symptoms, improvement of the patients' life quality and is particularly justified in patients with counter-indication to the standard pharmacotherapy of allergic rhinitis.

The Effectiveness of the Bacteria Derived Extremolyte Ectoine for the Treatment of Allergic Rhinitis

“…The study of Abdulkerimov et al was of particular interest to us as the combination of ectoine and INS showed the best treatment effect in difficult-to-treat patients with moderate-to-severe rhinitis symptoms. This trend was also observed for the most effective intranasal formulation (azelastine and fluticasone furoate) in patients with moderate-to-severe rhinitis who exhibited complete or near-complete symptom relief faster than those receiving either fluticasone furoate or azelastine alone [46].…”

“…Only 3 of the selected studies applied a randomization [ 43 , 46 , 50 ], whereas 3 did not carry out randomization due to local regulatory restrictions [ 47 , 49 ]. Two studies were single-arm trials [ 44 , 45 ], and the remaining studies did not present any information regarding randomization.…”

“…(a) Application of ENS concomitantly with drugs compared to application of drugs alone [46,[50][51][52][53](Table 2)…”

“…Mokronosova et al showed in 2 studies that treatment for 14 days with ENS resulted in successful treatment of 58.8% and >90% of patients, respectively [44,45]. According to Abdulkerimov et al [46], significant nasal symptom relief was evident within 18 to 21 days in moderate-to-severe rhinitis patients who underwent treatment with ENS. According Group 1: ENS (persistent allergic rhinitis) After 10 days of treatment, both groups showed a significant reduction in complaints: the total clinical score developed from 4:6 ± 0:7 points to 0:7 ± 0:4 points in group 1 and from 5:3 ± 1:0 points to 0:4 ± 0:2 points in group 2.…”

“…Intranasal corticosteroids (INS) (mometasone, fluticasone, beclomethasone) [46][47][48] Oral or local antihistamine or local cromoglicate [49,50] Standard of care (guideline conform use of antihistamine and cromoglicate) [51][52][53] Intranasal isotonic salt solution [43,54,55] Only 3 of the selected studies applied a randomization [43,46,50], whereas 3 did not carry out randomization due to local regulatory restrictions [47,49]. Two studies were single-arm trials [44,45], and the remaining studies did not present any information regarding randomization.…”